TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis.

Front Cell Neurosci · 2024 · PMC11150779 · PMID 38841204

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, the number of the differentiating OL (Olig2 + CC1 + ) within the lesions showed a trend towards increased differentiation in the TPPB-treated group when compared to the control group at 15 dpl ( Figure 5C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.